- Clone:
- REA213 | TREM-26
- Type of antibody:
- Primary antibodies, Recombinant antibodies
- Isotype:
- recombinant human IgG1
- Applications:
- FC Glossary
- Select a conjugate:
- Select a size:
Related products for CD354 (TREM-1) Antibody, anti-human, REAfinity™
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Cells were incubated with an excess of purified unconjugated CD354 (TREM-1) (REA213) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
Flow cytometric comparison of different clones for CD354 (TREM-1). Human peripheral blood mononuclear cells (PBMCs) after erythrocyte lysis were stained with CD354 (TREM-1) antibodies and with a suitable counterstaining. As a control, CD354 (TREM-1) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
Comparison of staining pattern on non-fixed and fixed cells using CD354 (TREM-1) (REA213). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Clone REA213 recognizes the human CD354 (TREM-1), a 30 kDa member of the triggering receptors expressed on myeloid cells (TREM) family of cell surface receptors. TREM receptors are immunoglobulin 'superfamily' members and contain a single variable-type immunoglobulin domain. Human TREM cluster is located on chromosome 6p21. Expression of TREM-1 is found on the cell surface of myeloid cells such as neutrophils, monocytes, dendritic cells, and macrophages. TREM-1 signals via ITAM-containing adaptor DAP12 and serves as an amplifier of cell activation in response to triggers such as LPS. TREM-1 activated cellular signalling molecules and pathways lead to generation of pro-inflammatory response such as expression and secretion of chemokines and cytokines including MCP-1, MIP-1a, interleukin 6 (IL-6), IL-8, and TNF. TREM-1 acts in a concerted manner with other signalling receptors such as TLRs and Nod-like receptors, leading to an amplification of the initial response. Expression of TREM-1 itself is upregulated in response to presence of LPS, microbial products, and cytokines released during activation response. A soluble form of TREM-1 (sTREM-1) is also detected in fluids from patients with infections.
Additional information: Clone REA213 displays negligible binding to Fc receptors.
TREM1
Technical specifications
Recombinant antibodies at Miltenyi Biotec
As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.
The Miltenyi way of generating best-in-class antibodies and antibody conjugates
At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.
Infusing our unique expertise
Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.
Maximizing value for your research
By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:
reduce undesirable binding to Fc gamma receptors,
- eliminate destabilizing amino acid motifs,
- increase specific bonding affinity for stronger, more accurate targeting, and
- optimize fluorochrome conjugation for brighter and clearer signals.
In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.
Better science with quality antibodies
Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.